A wealth of information, in particular in experimental models, suggests a role for the gut microbiota in bidirectionally modulating brain inflammation in MS, with changes in bacterial composition inducing upregulation vs. downregulation of the production of IL-1β and other inflammation-related factors (84–87). The gene discussed is IL1B; the disease is myeloid sarcoma.